首页> 外文期刊>The Journal of Pathology: Clinical Research >Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix
【24h】

Introducing a novel highly prognostic grading scheme based on tumour budding and cell nest size for squamous cell carcinoma of the uterine cervix

机译:介绍一种基于肿瘤萌芽和细胞巢大小的新型高预后分级方案,用于宫颈鳞状细胞癌

获取原文
       

摘要

A novel histopathological grading system based on tumour budding and cell nest size has recently been shown to outperform conventional (WHO‐based) grading algorithms in several tumour entities such as lung, oral, and oesophageal squamous cell carcinoma (SCC) in terms of prognostic patient stratification. Here, we tested the prognostic value of this innovative grading approach in two completely independent cohorts of SCC of the uterine cervix. To improve morphology‐based grading, we investigated tumour budding activity and cell nest size as well as several other histomorphological factors (e.g., keratinization, nuclear size, mitotic activity) in a test cohort ( n ?=?125) and an independent validation cohort ( n ?=?122) of cervical SCC. All parameters were correlated with clinicopathological factors and patient outcome. Small cell nest size and high tumour budding activity were strongly associated with a dismal patient prognosis ( p ??0.001 for overall survival [OS], disease‐specific survival, and disease‐free survival; test cohort) in both cohorts of cervical SCC. A novel grading algorithm combining these two parameters proved to be a highly effective, stage‐independent prognosticator in both cohorts (OS: p ??0.001, test cohort; p ?=?0.001, validation cohort). In the test cohort, multivariate statistical analysis of the novel grade revealed that the hazard ratio (HR) for OS was 2.3 for G2 and 5.1 for G3 tumours compared to G1 neoplasms ( p ?=?0.010). In the validation cohort, HR for OS was 3.0 for G2 and 7.2 for G3 tumours ( p ?=?0.012). In conclusion, our novel grading algorithm incorporating cell nest size and tumour budding allows strongly prognostic histopathological grading of cervical SCC superior to WHO‐based grading. Therefore, our data can be regarded as a cross‐organ validation of previous results demonstrated for oesophageal, lung, and oral SCC. We suggest this grading algorithm as an additional morphology‐based parameter for the routine diagnostic assessment of this tumour entity.
机译:最近显示出一种基于肿瘤萌芽和细胞巢大小的新型组织病理学分级系统,在预后患者方面,其在多个肿瘤实体(例如肺,口腔和食道鳞状细胞癌(SCC))中的表现优于常规(基于WHO)的分级算法分层。在这里,我们在两个完全独立的子宫颈SCC队列中测试了这种创新的分级方法的预后价值。为了改善基于形态学的分级,我们在一个测试队列(n = 125)中调查了肿瘤发芽活性和细胞巢大小以及其他几个组织形态学因素(例如,角化,核大小,有丝分裂活性)。 (n≥122)。所有参数均与临床病理因素和患者预后相关。在两个子宫颈SCC患者中,小细胞巢大小和高的肿瘤萌发活性与患者预后不佳(总体生存率[OS],疾病特异性生存率和无疾病生存率p≤0.001)密切相关。 。结合这两个参数的新颖分级算法在两个队列中均被证明是高效,独立于阶段的预后指标(OS:p≤0.001,测试队列;p≤0.001,验证队列)。在试验队列中,新等级的多变量统计分析显示,与G1肿瘤相比,G2肿瘤OS的危险比(HR)为2.3,G3肿瘤为5.1(p = 0.010)。在验证队列中,G2肿瘤OS的HR为3.0,G3肿瘤OS的HR为7.2(p = 0.0121)。总而言之,我们新颖的分级算法结合了细胞巢大小和肿瘤萌芽,可对宫颈SCC的预后组织病理学分级进行强有力的预测,优于WHO分级。因此,我们的数据可视为对食管,肺和口腔SCC的先前结果的跨器官验证。我们建议将此分级算法作为对该肿瘤实体的常规诊断评估的另一个基于形态学的参数。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号